|Year : 2019 | Volume
| Issue : 6 | Page : 1981-1986
Assessment of family physicians' awareness and knowledge of familial hypercholesterolemia in governmental hospitals in Riyadh, Saudi Arabia
Maha Mohammed Arnous, Abdullah Mohammed Alghamdi, Medhat A Ghoraba
Department of Family Medicine, Security Forces Hospital, Riyadh, Saudi Arabia
|Date of Submission||05-Apr-2019|
|Date of Decision||07-Apr-2019|
|Date of Acceptance||19-Apr-2019|
|Date of Web Publication||26-Jun-2019|
Dr. Maha Mohammed Arnous
Department of Family Medicine, Security Forces Hospital, Riyadh - 12625
Source of Support: None, Conflict of Interest: None
Background: Familial Hypercholesterolemia (FH) is an inherited and complex multifactorial disease that can lead to early onset of coronary artery disease (CAD). Diagnosis, treatment, and management of FH require a well-trained physician with high awareness of the disease and different risk factors to avoid complications. Materials and Methods: This cross-sectional study evaluated family physicians' awareness and knowledge of FH using self-administered questionnaires in governmental hospitals in Riyadh, Saudi Arabia, during 2018. Results: A total of 225 family physicians completed the questionnaire, with a response rate of 58.4%. The mean age of respondents was 31.3 years and more than 59.1% were men. Although 72.4% of physicians rated their familiarity with FH as average and above, 48.4% of all participants had poor FH knowledge, while only 51.6% had acceptable FH knowledge. About 65.8% of physicians reported that they routinely take a detailed family history, perform a physical examination, and screen close relatives. Awareness of various clinical algorithms for diagnosis of patients with FH was very low at 52.0%. The mean FH knowledge and familiarity scores were significantly higher (P < 0.001) among participants who were older, had higher training levels, or longer years in practice. Conclusions: The current study revealed significant deficits in FH familiarity, awareness, knowledge, and practice among Saudi physicians. FH educational programs directed at all physicians involved in FH patients' management are necessary to improve physicians' knowledge of all aspects of FH management, including the importance of a mechanism for identifying people at risk for a genetic condition by a process of systematic family tracing.
Keywords: Cholesterol, coronary artery disease, familial hypercholesterolemia, genetic, questionnaire
|How to cite this article:|
Arnous MM, Alghamdi AM, Ghoraba MA. Assessment of family physicians' awareness and knowledge of familial hypercholesterolemia in governmental hospitals in Riyadh, Saudi Arabia. J Family Med Prim Care 2019;8:1981-6
|How to cite this URL:|
Arnous MM, Alghamdi AM, Ghoraba MA. Assessment of family physicians' awareness and knowledge of familial hypercholesterolemia in governmental hospitals in Riyadh, Saudi Arabia. J Family Med Prim Care [serial online] 2019 [cited 2021 Jun 15];8:1981-6. Available from: https://www.jfmpc.com/text.asp?2019/8/6/1981/261410
| Introduction|| |
Familial Hypercholesterolemia (FH) is a complex, inherited, multifactorial disease characterized by elevated levels of serum low-density lipoprotein cholesterol (LDL-C), which results in excess deposition of cholesterol, and is one of the most common dominant autosomal diseases encountered in clinical medicine., The estimated global prevalence of heterozygous FH (HeFH) is 1 in 500, although prevalence is considerably higher in some populations because of founder effects. Although homozygous FH is uncommon (general prevalence < 1/1000000), it is a critical condition that commences in infancy.
The magnitude of the problem in the Middle East, including Saudi Arabia, is largely unknown. FH is caused by mutations in the genes coding for low-density lipoprotein receptors, apolipoprotein B, or Proprotein Convertase Subtilase/Kexin type 9 (PCSK9). Untreated FH increases risk of early-onset coronary artery disease (CAD) by 10–20 times,, while early diagnosis and treatment can improve morbidity and mortality from CAS  Worldwide, at least 20 million people have FH; the majority remain undetected because of lack of country-specific FH guidelines  and of physicians specifically trained and practicing as lipid experts. Additionally, primary care physicians (PCPs) practicing in suburban and rural regions may not have access to specialist services. Hence, current treatment is suboptimal.
Several tools are available for diagnosis of adults with FH, including the Make Early Diagnosis to Prevent Early Death, Simon Broome, and Dutch Lipid Clinic Network (DLCN) criteria; however, the DLCN criteria are widely used because of their higher sensitivity.,
Opportunistic screening by GPs could address the low reporting of FH and subsequently improve patient outcomes.,, Around 92% of lipid profiles in the community were requested by GPs, confirming that they play an essential role in detecting individuals with FH. However, physicians' FH knowledge and awareness is suboptimal.,,, Additionally, varying specialties (PCPs versus specialists) do not differ significantly in their FH knowledge and awareness.
The current study aimed to assess FH awareness and knowledge among family physicians in Riyadh, Saudi Arabia, and to compare FH familiarity with physician characteristics, including age, gender, years of practice, and level of training.
| Materials and Methods|| |
Setting and IRB approval
This multi-center cross-sectional study was conducted among family physicians working at five governmental hospitals at Security Forces Hospital, Prince Sultan Military Medical City, King Fahad Medical City, King Abdulaziz Medical City and King Khalid University Hospital in Riyadh, Saudi Arabia between November and December 2018 using an anonymous self-administered electronic questionnaire in English distributed among family physicians working in the above-mentioned medical centers in all different professional levels aged below 60 years and any physicians from other specialties than family medicine and other healthcare professionals were excluded.
The study was approved by the Institutional Review Board College of Medicine, King Saudi University (no. E-16-1824) and ethical approval was taken from Security Forces Hospital Program Research Committee.
A reliable and validated questionnaire was adopted from a previous similar study in Saudi Arabia. This questionnaire was basically developed by Bell et al. and Pang et al. with some additional questions by Batais et al. based on previous expert recommendations and international guidelines dealing with FH management.,, The questionnaire was initially tested by 20 physicians at King Khalid University Hospital in Riyadh, Saudi Arabia to ensure the questions were clear, understandable, and logically ordered. A month later, the questionnaire was re-administered to the same group to ensure reliability and consistency. We used Kappa test agreement measures between test and retest; the average kappa value was 0.85 (P < 0.001). The questionnaire's reliability coefficient (Cronbach's alpha) in this pilot study was >0.7.
The questionnaire consisted of two main sections. The first section assessed physician's demographic data including, gender, qualifications and training status, years of practice, and number of patients seen in clinic per month. the second section was questions about FH knowledge, practice, detection, and awareness, [see [Table 1]] Participants selected one correct answer to questions from a list of options provided. There were no open-ended questions.
|Table 1: Summary of physicians' responses to questions about FH knowledge, practice, detection, and awareness|
Click here to view
The sample size was calculated based on the results of the pilot study, where 68.7% of participants reported their familiarity with FH as average and above average. The appropriate sample size was calculated to be 331 participants based on a 5% margin of error, a confidence interval of 95%, and 68.7% average or above average familiarity with FH. Considering the nonresponse rate of 20%, the survey questionnaire was distributed to 385 participants.
You should write first how you calculated your sample size Data were analyzed using SPSS 22 (IBM Corp., New York). Continuous variables were expressed as mean ± standard deviation; categorical variables were expressed as percentages. Chi-square tests were used for categorical variables. T-tests and one-way ANOVA were used for continuous variables. Logistic regression was used to assess risk factors. A P value < 0.05 was considered statistically significant.
| Results|| |
[Table 2] shows the participants characteristics. The questionnaire was distributed to 385 family physicians; 225 returned completed questionnaires, for a response rate of 58.4%. Respondents' mean age (±SD) was 31.32 (±7.63) years, with 6.69 (±8.81) mean years of practice; more than half (59.11%) were men, and more than two-thirds (70.22%) were general practitioners (GPs), and one third (29.78%) were cardiologists, endocrinologists, gynecologists, internists, and pediatricians.
Knowledge of FH management
Most family physicians (72.40%) rated their familiarity with FH as average and above [see [Table 2]]. The mean (±SD) overall FH knowledge score was 5.65 (±2.15). [Table 1] summarizes participants' overall FH knowledge. The clinical description of FH was underestimated by 56.4% of participants. Only 19.6% of physicians correctly identified the general prevalence of HeFH as 1:500, and only a third (33.8%) recognized its inheritance pattern. CVD risk in untreated FH patients was correctly scored by 5.8% of respondents as 20 times that of the general population; less than half (40.9%) of physicians could not identify the age threshold for premature CVD in males and the same percentage could not identify it in females. Only 40% of physicians knew that genetic testing was not required to accurately diagnose FH. Only 32% of physicians selected LDL-C < 2.5 mmol/L as the target for adults with FH, while 42.7% selected LDL-C < 1.8 mmol/L as the target for FH adults with known CAD or diabetes. Statins, as the first-line medication for treating FH patients, were selected by 59.6% of physicians. The preferred combination to treat severe hypercholesterolemia is statins plus ezetimibe, which was selected by 37.3% of physicians. Data are shown in [Table 1].
About two-thirds (65.8%) of physicians reported that they routinely take a detailed family history, perform a physical examination, and screen close relatives of all patients with premature CAD. The screening for lipid profile for adults with FH was 32.0% and for FH adults with known CAD or diabetes was 42.7%. Of the respondents, 30.2% diagnosed patients with FH, and 32% managed FH patients under their care. The most prevalent age for screening young people for FH is 13–18 years, which was selected by 31.6% of physicians [Table 1].
Opinions and FH detection
Most participants (84%) selected family physicians as the most effective in detecting early FH and screening first-degree relatives. Laboratory comments on lipid profile alerting to possible FH, a direct telephone call from the laboratory, and alerts by the clinical software system, were all selected as the preferred choice in helping physicians detect FH by only (38.2%) of respondents [Table 1].
Awareness of FH management
The results showed that awareness of various clinical algorithms for FH diagnosis was very low; 14.7% identified the DLCN criteria, 14.7% the Simon Broome criteria, and 17.3% the US MedPed Program. A high percentage (73.3%) were unaware of cascade screening for patients with FH, and 52.4% were unaware of specialized clinical services for lipid disorders to which patients can be referred. A clear majority were unaware of new FH medications besides statins, including PCSK9 inhibitors (73.8%), Mipomersen (an antisense oligonucleotide inhibitor) (90.2%), and Lomitapide (MTP) inhibitors (84%) [Table 1]].
Regarding relationships between FH familiarity and mean knowledge scores and physician demographics overall, 48.4% of participants had poor FH knowledge, while only 51.6% had acceptable knowledge. Of the 51.6% of physicians with acceptable knowledge, 55.2% rated their FH familiarity as average and above. There were no significant associations between FH familiarity and physicians' demographics except for years of practice (P < 0.05) [Table 3].
|Table 3: The relationship between FH familiarity and physicians' demographics|
Click here to view
Logistic regression analysis showed that participants with > 15 years' experience were 88% less likely to be familiar with FH compared to those with ≤5 years' experience (OR = 0.129, 95% CI = 0.017–0.997, P < 0.049) [Table 4].
|Table 4: Low familiarity with FH as predicted by physicians' characteristics|
Click here to view
The mean knowledge scores by physicians' characteristics and FH familiarity were calculated [see [Table 5]]. The mean knowledge score increased significantly (P < 0.001) with age, being highest (7.13) among those aged >45 years. There was a significant difference (P < 0.001) in mean knowledge score by training level, being highest among residents at 6.92, and lowest among general practitioners at 5.23. The mean knowledge score of physicians who rated their familiarity with FH as “average and above” was significantly (P < 0.002) higher compared to those who rated it as “below average,” at 5.92 versus 4.93, respectively.
|Table 5: Mean knowledge score by physicians' characteristics and FH familiarity|
Click here to view
[Figure 1] shows a summary of physician responses to the most selected risk factors that further increase CVD risk in patients with FH. In general, 59.6% of participants identified smoking as a risk factor, 50.7% selected type 2 diabetes, and 39.1% selected elevated Lp (a).
|Figure 1: Physician responses to the most selected risk factors that further increase CVD risk in patients with FH|
Click here to view
| Discussion|| |
We conducted this cross-sectional survey to determine FH knowledge, awareness, detection, and clinical practices of family medicine physicians in Riyadh, Saudi Arabia, a country well known for its high consanguinity rate and underreporting of FH mutations, indicating poor awareness of CVD genetic risks. Consistent with a previous study Batais in Saudi Arabia in 2017, most participants rated themselves as average and above average in FH familiarity, at 68.7%, and 72.4%, respectively. However, this contrasts with the results of Rangarajan study in 2016 in Tamil Nadu, where only 27.9% of participants rated their familiarity as average and above. Generally, overall FH knowledge among family physicians in Riyadh can be considered average, a result which is better compared to the previous Saudi study. The current study revealed significant deficits in FH familiarity among Saudi physicians even though most of them perceived their familiarity with FH as average and above average. A very low percentage (5.8%, and 19.6%) correctly identified the CVD risk in untreated FH and the general prevalence of HeFH. Additionally, a low percentage (<40%) correctly identified LDL-C targets for adults with FH, correctly identified the transmission rate to first-degree relatives, and selected a combination of statin and ezetimibe to treat severe hypercholesterolemia.
Similarly, the data highlighted substantial deficits in FH awareness, especially of various clinical algorithms for FH patients' diagnosis, cascade screening, and of new, non-statin medications for FH, such as Mipomersen. Such findings are consistent with A UK-based survey in 2016 in France, Rangarajan study in 2016 in Tamil Nadu, Asia-Pacific countries: a pilot study in 2015 and Bell DA data in western Australia and Batais study in Saudi Arabia in 2017,,,,, and indicate significant gaps in knowledge and awareness of FH. Therefore, our study demonstrates the need and importance of conducting successful educational intervention and training programs for family physicians regarding FH.
Achieving the optimal target LDL-C levels of FH patients of <2.5 mmol/L or <1.8 mmol/L with known atherosclerotic cardiovascular disease is imperative to reducing lifetime CVD risk.,, In the current study, less than half of respondents correctly identified LDL-C targets for FH adults and for FH adults with known CAD or diabetes. This was consistent with Batais et al.'s results, with an even lower percentage of correct answers.
Being aware of potential therapeutic options for FH is critical for appropriate management. The current data revealed that most physicians were unaware of highly effective new medications for lowering LDL-C, illustrated by increased use of PCSK9 inhibitors. This finding resembles the findings of Batais et al. and Schofield et al.
Consistent with previous studies from Saudi Arabia, Asia, and the United Kingdom (UK),,, most respondents in the current study selected family physicians as the most effective health care provider for detecting FH early and screening first-degree relatives. A different finding was reported from Western Australia where most GPs described themselves as the most effective healthcare provider to detect FH, even though this study showed that GPs had suboptimal awareness and knowledge of FH.
Only 39% of family physicians in the current study recognized increased Lp (a) as an adjunctive risk factor in FH patients. This is considered a low percentage compared to what was reported in Japanese, Taiwanese, and Korean studies at 51%, 66%, and 83%, respectively.
In contrast to a similar previous Saudi study, the current study showed that more than half of participants had acceptable FH knowledge (7.1% versus 51.6%). Our findings highlighted that FH familiarity scores tended to be higher among physicians with more experience, indicating that experience improves their ability to effectively manage FH, which agrees with the previous study's results.
The current study findings highlighted the need for ongoing FH educational programs, that should be directed to all physicians involved in FH patients' management, since such education programs have been implemented in the UK and significantly improved physicians' knowledge in all aspects of FH management, including the importance of cascade screening.
The main limitations of this study were the small sample size and the cross-sectional design.
Authors acknowledge all primary authors of the included studies for their assistance and academic support.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Wong SL, Garg AK. Familial hypercholesterolemia: A call for increased awareness in the Asian Indian population. Austin J Clin Pathol 2014;1:1-9.
Soutar AK, Naoumova RP. Mechanisms of disease: Genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007;4:214-25.
Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, et al
. Estimating the prevalence of heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. BMJ Open 2017;7:e016461.
Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: A HuGE association review. Am J Epidemiol 2004;160:421-9.
Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al
. Homozygous familial hypercholesterolemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolemia of the european atherosclerosis society. Eur Heart J 2014;35:2146-57.
Alghamdi M, Aljohani E. Clinical outcome of familial hypercholesterolemia (FH) at King Abdulaziz Medical City, Riyadh-A 20-year experience. J Saudi Heart Assoc 2013;25:149.
Ahmed W, Whittall R, Riaz M, Ajmal M, Sadeque A, Ayub H, et al
. The genetic spectrum of familial hypercholesterolemia in Pakistan. Clin Chim Acta 2013;421:219-25.
Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49:476-88.
Ashavaid T, Altaf A, Nair K. Molecular basis of familial hypercholesterolemia: An Indian experience. Indian J Clin Biochem 2000;15:11-9.
Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al
. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolemia: a prospective registry study. Eur Heart J 2008;29:2625-33.
Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al
. Integrated guidance on the care of familial hypercholesterolemia from the International FH foundation. Int J Cardiol 2014;171:309-25.
Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al
. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171-6.
Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-6.
World Health Organization. Familial Hypercholesterolemia: Report of a Second WHO Consultation. Geneva, Switzerland: World Health Organization; 1999. WHO publication No. WHO/HGN/FH/CONS/99.2.
Hadfield SG, Humphries SE. Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol 2005;16:428-33.
Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, et al
. Familial hypercholesterolemia: A model of care for Australasia. Atheroscler Suppl 2011;12:221-63.
Humphries SE, Hadfield G. Identifying patients with familial hypercholesterolemia in primary care. Heart 2008;94:695-6.
Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R, NICE Guideline Development Group. Identification and management of familial hypercholesterolemia: What does it mean to primary care? Br J Gen Pract 2009;59:773-8.
Bell DA, Hooper AJ, Bender R, McMahon J, Edwards G, van Bockxmeer FM, et al
. Opportunistic screening for familial hypercholesterolemia via a community laboratory. Ann Clin Biochem 2012;49:534-7.
Schofield J, Kwok S, France M, Capps N, Eatough R, Yadav R, et al
. Knowledge gaps in the management of familial hypercholesterolemia. A UK based survey. Atherosclerosis 2016;252:161-5.
Rangarajan N, Balasubramanian S, Pang J, Watts GF. Knowledge and awareness of familial hypercholesterolemia among registered medical practitioners in Tamil Nadu: Are they suboptimal? J Clin Diagn Res 2016;10:OC52.
Pang J, Sullivan DR, Harada-Shiba M, Ding PY, Selvey S, Ali S, et al
. Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: A pilot study. J Clin Lipidol 2015;9:42-8.
Bell DA, Garton-Smith J, Vickery A, Kirke AB, Pang J, Bates TR, et al
. Familial hypercholesterolemia in primary care: Knowledge and practices among general practitioners in Western Australia. Heart Lung Circ 2014;23:309-13.
Batais MA, Almigbal TH, Bin Abdulhak AA, Altaradi HB, AlHabib KF. Assessment of physicians' awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: Is there a gap? PLoS One 2017;12:e0183494.
Al Rasadi K, Almahmeed W, AlHabib KF, Abifadel M, Farhan HA, AlSifri S, et al
. Dyslipidemia in the Middle East: Status and a call for action. Atherosclerosis 2016;252:182-7.
Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al
. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013;34:3478-90.
Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. J Lipid Res 2009;50:S172-7.
Stock J. New EAS consensus statement on FH: Improving the care of FH patients. Atherosclerosis 2013;231:69-71.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]
|This article has been cited by|
||Are patients affected by chronic non-communicable diseases aware of their own clinical and laboratory parameters? A cross-sectional study from the south of Saudi Arabia
| ||Ibrahim M. Gosadi,Khaled A. Daghriri,Abdullah A. Otayf,Abdulrhman A. Nemri,Abdulaziz A. Kaal,Abdullah M. Qussadi,Manal M. Maashi,Alshaymaa M. Arishy,Hadeel M. Mushafa,Abdulrhman M. Salim |
| ||Saudi Journal of Biological Sciences. 2021; |
|[Pubmed] | [DOI]|
||Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting
| ||Moeber Mahzari,Hawazen Zarif |
| ||Advances in Therapy. 2021; |
|[Pubmed] | [DOI]|